Form D · Other
Cornovus Pharmaceuticals Inc.
Farmington, CT · CIK 0001600112
Offering snapshot reported Jan 26, 2024 · SEC filing
- Reported sold
- $500K Offering amount: $2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Jan 22, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 26, 2024 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Aug 11, 2016 | Initial | $982,600 | No comparison | 2 | SEC filing |
| Mar 3, 2014 | Initial | $1,590,944 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-503578
Source: Form D, filed Jan 26, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bruce Liang | Director |
| Glenn Mattes | Director, Executive |
| Raymond Neag | Director |
| Timothy Shannon | Director |
| Robert Mark Van Allen | Executive |
| R. Mark Van Allen | Executive |
| Daniel Wagner | Director |
Issuer details
Industry: Other (See others in industry)
Address:
400 Farmington Avenue
Farmington, CT, 06032
Farmington, CT, 06032